30 Aug 2023 , 03:27 PM
Strides Pharma Science Ltd’s Singapore subsidiary, Strides Pharma Global Pte. Ltd, secures approval from USFDA for generic Mycophenolate Mofetil. The medication is intended for oral suspension and serves organ transplant patients to prevent rejection.
The approval covers Mycophenolate Mofetil of strength 200 mg/ml, as stated in Strides Pharma Science’s regulatory filing. This generic product is both bioequivalent and therapeutically equivalent to the reference listed drug (RLD) CellCept for oral suspension, with a strength of 200 mg/ml from Roche Palo Alto, LLC.
The approval reinforces Strides’ existing Mycophenolate Mofetil portfolio, which already encompasses several products. Manufacture of the approved product will occur at the company’s Bengaluru facility, according to Strides.
The market size for Mycophenolate Mofetil for oral suspension stands at USD 41 million, based on IQVIA data as noted by the company.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.